← 返回

TRIM59 通过泛素-蛋白酶体降解 IRF3 促进肺腺癌的免疫逃逸和肿瘤进展

英文原题:TRIM59 promotes immune evasion and tumor progression in lung adenocarcinoma via ubiquitin- proteasomal degradation of IRF3.

查看英文原题

TRIM59 promotes immune evasion and tumor progression in lung adenocarcinoma via ubiquitin- proteasomal degradation of IRF3.

PubMed 2026/05/20(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肺腺癌(LUAD)仍是癌症相关死亡的主要原因之一,免疫逃逸是治疗耐药和预后不良的关键驱动因素。含三重基序(TRIM)家族的E3泛素连接酶在调控肿瘤免疫中发挥关键作用,但大多数TRIM成员在LUAD中的功能相关性和分子机制仍不清楚。

在此,我们整合多组学分析与功能实验,系统研究了TRIM家族在LUAD中的预后价值和免疫调节作用。我们确定TRIM59是一个独立的预后不良因素,其高表达与免疫抑制性肿瘤微环境(TME)相关。在机制上,TRIM59与干扰素调节因子3(IRF3)相互作用,促进其泛素化和蛋白酶体降解,从而抑制IRF3-STING通路及下游抗肿瘤干扰素的产生。单细胞分析揭示了IRF3的细胞类型特异性功能:在肿瘤细胞中,IRF3可能抑制免疫激活基因表达并调节增殖;在肿瘤浸润T/NK细胞中,IRF3负向调控促炎信号。

总之,我们的发现确立了TRIM59-IRF3轴作为驱动LUAD免疫逃逸的新调控通路,为增强免疫治疗疗效提供了有前景的预后生物标志物和治疗靶点。

展开英文摘要原文

Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality, with immune evasion being a key driver of treatment resistance and poor prognosis. The tripartite motif-containing (TRIM) family of E3 ubiquitin ligases plays critical roles in regulating tumor immunity, but the functional relevance and molecular mechanisms of most TRIM members in LUAD remain elusive.

Here, we integrated multi-omics analyses with functional experiments to systematically investigate the prognostic value and immunoregulatory role of TRIM family in LUAD.

We identified TRIM59 as an independent poor prognostic factor, with its high expression correlating with an immunosuppressive tumor microenvironment (TME).

Mechanistically, TRIM59 interacts with interferon regulatory factor 3 (IRF3) and promotes its ubiquitination and proteasomal degradation, thereby inhibiting the IRF3-STING pathway and downstream anti-tumor interferon production.

Single-cell analyses revealed cell-type-specific functions of IRF3: in tumor cells, IRF3 may suppresses immune-activating gene expression and modulates proliferation; in tumor-infiltrating T/NK cells, IRF3 negatively regulates pro-inflammatory signaling. Collectively, our findings establish the TRIM59-IRF3 axis as a novel regulatory pathway driving LUAD immune evasion, providing a promising prognostic biomarker and therapeutic target for enhancing immunotherapy efficacy.

论文信息

作者
Li X、Guo M、Lian Z
第一作者单位
Department of Radiation Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.China
通讯作者单位
Department of Emergency, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.China
期刊
Frontiers in immunology2026
原文标识
PubMed 42245669 · DOI 10.3389/fimmu.2026.1813280